NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Mar 2008
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Clinical Trials (5)
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Started Oct 2014
20 enrolled
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Grade 1 Follicular Lymphoma+5 more
A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia
Started Oct 2014
0Chronic Lymphocytic Leukemia
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
Started Aug 2013
16 enrolled
Hodgkin LymphomaNon-Hodgkin LymphomaAcute Leukemia
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Started May 2012
26 enrolled
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
Started May 2012
Loss of Exclusivity
LOE Date
Apr 26, 2031
62 months away
Patent Expiry
Apr 26, 2031
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8895756 | Jan 12, 2026Expired | Product | — |
| 8609863 | Jan 12, 2026Expired | Product | — |
| 8791270 | Jan 12, 2026Expired | Product | U-1542 |
| 8791270*PED | Jul 12, 2026 | — | |
| 8895756*PED | Jul 12, 2026 | — |
Company
Teva
Israel - Petach Tikva